UCB Aims To Tailor Myasthenia Gravis Therapy Options To Patients
With Two Late-Stage Candidates
Belgium’s UCB Pharma is expecting progress with new candidates for myasthenia gravis, psoriasis and osteoporosis this year.
You may also be interested in...
Public Company Edition: Among other recent large financings, BridgeBio Pharma launched a $650m note sale, CureVac closed a $517.5m follow-on offering and Revolution Medicines raised $260.9m.
UCB's R&D efforts include late-stage diverse but complementary immunologicals and anti-neuroinflammatories.
The European Commission has granted a marketing authorization for UCB and Amgen’s bone-building MAb, romosozumab, and first launches are expected in the first half of 2020; patient groups suggest that the prevention and treatment of fragility fractures has not attracted the attention it deserves.